胃癌新辅助治疗局部进展期胃癌病理完全缓解8例临床特征分析

CLINICAL CHARACTERISTICS OF LOCAL ADVANCED GASTRIC CANCER WITH PATHOLOGICAL COMPLETE RESPONSE FOLLOWING THE NEOADJUVANT CHEMOTHERAPY:AN ANALYSIS OF EIGHT PATIENTS

目的分析胃癌新辅助治疗局部进展期胃癌原发灶病理学完全缓解(pathological complete response,pCR)患者的临床特征。方法筛选哈尔滨医科大学附属肿瘤医院2007年7月1日—2015年12月30日期间胃癌新辅助化疗原发病灶完全缓解的8例患者的临床资料,分析其临床特征;结合目前已有的临床试验结果讨论其个体化治疗策略。结果 8例患者治疗前均为局部进展期胃癌,2例接受SOX方案(替吉奥+奥沙利铂),2例接受XELOX方案(希罗达+奥沙利铂),1例接受TS方案(替吉奥+艾素),1例接受LF方案(希罗达+草铂),1例接受替吉奥+紫杉醇方案,1例接受多西他赛+奥沙利伯方案。结论胃癌新辅助化疗能有效改善胃癌总生存率,但是现有的胃癌新辅助治疗方案的pCR率较低,需要进一步探究新的、高效的化疗方案,实现真正的个体化治疗。

Objective To analyze the clinical characteristics of advanced gastric cancer patients with pathological complete response（pCR）following neoadjuvant chemotherapy.Methods The clinical data of gastric cancer patients who had undergone neoadjuvant chemotherapy from July 1,2007 to December 30,2015 in author＇s hospital were collected and eight patients were found to be pCR with their primary lesion;combined with the results of the neoadjuvant chemotherapy and discussed the strategy of individualized treatment.Results All the eight patients were local advanced gastric cancer,they received different projects,such as SOX,XELOX,TS,LF and so forth.Conclusion The gastric cancer neoadjuvant chemotherapy can efficiently improve the survival rate,but the pCR rate is fairly low for the available neoadjuvant chemotherapy regimen.We should move forward a single step to study the new and high-performance regimen and really come true the individualized treatment.